Data / Form D filings / RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc.: Form D filings
RespireRx Pharmaceuticals Inc., a biotechnology company in Glen Rock, NJ, filed 14 Form D notices with the SEC between 2009 and 2020. The latest, on August 12, 2020, reports $193,250 sold of a $193,250 offering to 2 investors.
Find out what RespireRx Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 126 VALLEY ROAD, SUITE C, Glen Rock, NJ, 07452
- Phone
- (201) 444-4947
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 849636
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 12, 2020 | New notice | $193,250 | $193,250 | $0 | 2 | Jul 2, 2020 | sec.gov |
| Aug 12, 2020 | New notice | $2,000,000 | $0 | $2,000,000 | 1 | Jul 28, 2020 | sec.gov |
| Sep 24, 2018 | New notice | $1,500,000 | $250,750 | $1,249,250 | 10 | Sep 12, 2018 | sec.gov |
| Sep 13, 2017 | New notice | $1,150,000 | $75,000 | $1,075,000 | 1 | Aug 29, 2017 | sec.gov |
| Mar 23, 2017 | New notice | $1,500,000 | $50,000 | $1,450,000 | 1 | Mar 10, 2017 | sec.gov |
| Jan 13, 2017 | New notice | $3,000,000 | $185,000 | $2,815,000 | 4 | Dec 29, 2016 | sec.gov |
| Jan 20, 2016 | New notice | $2,500,000 | $100,000 | $2,400,000 | 1 | Jan 8, 2016 | sec.gov |
| Sep 11, 2015 | New notice | $3,000,000 | $721,180 | $2,278,820 | 8 | Aug 28, 2015 | sec.gov |
| Nov 17, 2014 | New notice | $1,000,000 | $238,500 | $761,500 | 7 | Nov 5, 2014 | sec.gov |
| Apr 2, 2014 | New notice | $1,500,000 | $753,220 | $746,780 | 18 | Mar 18, 2014 | sec.gov |
| Aug 22, 2012 | New notice | $3,832,214 | $3,832,214 | $0 | 13 | Aug 10, 2012 | sec.gov |
| Oct 27, 2011 | New notice | $675,057 | $675,057 | $0 | 1 | Oct 20, 2011 | sec.gov |
| Jan 22, 2010 | New notice | $1,500,000 | $1,500,000 | $0 | 1 | Jan 15, 2010 | sec.gov |
| Aug 13, 2009 | New notice | $5,886,291 | $5,886,291 | $0 | 1 | Jul 31, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Richard E. Purcell | Executive Officer | |
| Arnold S. Lippa | Executive Officer, Director | |
| Kathryn E. MacFarlane | Director | |
| Jeff E. Margolis | Executive Officer, Director | |
| Timothy E. Jones | Executive Officer, Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
Every Form D from the week of Aug 10, 2020 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what RespireRx Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.